Chardan Capital Downgrades Outlook Therapeutics to Neutral
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Daniil Gataulin has downgraded Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral.
August 31, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Outlook Therapeutics has been downgraded from Buy to Neutral by Chardan Capital, which may impact the stock's performance.
Analyst ratings often influence the market's perception of a stock. A downgrade from Buy to Neutral suggests that the analyst sees less upside potential, which could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100